Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2 Positive Early-stage Breast Cancer

NCT06035016 · clinicaltrials.gov ↗

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Breast Cancer
Early-stage Breast Cancer

Interventions

DRUG: pyrotinib combined with Capecitabine
DRUG: treatment of physician's choice

Sponsor

Peking Union Medical College Hospital